Malondialdehyde as an indicator of ischaemic heart disease

Lipids are the most involved class of molecules among the many targets of oxidative stress. Lipid oxidation produces a number of secondary products. The principal and most studied product of polyunsaturated fatty acid peroxidation is malondialdehyde (MDA). Beside being a highly toxic molecule, malondialdehyde is also considered as a marker of lipid peroxidation. This study was intended to determine the lipid endoperoxide levels of some Turkish patients with ischaemic heart disease findings at coroner angiography and verify whether malondialdehyde could be an indicator of ischaemic heart disease. For this purpose lipid peroxide levels of the control and test groups were measured with spectrophotometric method which is based on the reaction between malondialdehyde and thiobarbituric acid. Statistical analysis of our results revealed a significant difference between the mean serum lipid peroxide levels of the patiens and the control group being 3.74±0.44 nmol/ml vs 2.72±0.53 nmol/ml respectively, and p=0.258. According to these results we concluded that presence of MDA in serum at certain levels may predict the insurgence of vascular pathologies.

PDF

___

1. Ceroni, C., Boraso, A., Cargnoni, AI., and Ferrari, R., Oxidative stress in cardiovascular disease: myth or fact? Arch. Biochem. Biphys.,420, 217-221, 2003.
2. Slatter, D.A., Bolton, C.H., and Bailey, A.J., The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia, 43, 550-557,2000.
3. Sohal, R.S., Mockett, R.J., and Orr, W.C., Mechanism of aging: an appraisal of the oxidative stress hypothesis. Free Radic. Biol Med., 33, 575-586, 2002.
4. Uchida, K., Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med., 28, 1685-1696, 2000.
5. Pryor, W. A., and Stanley, J. P., A suggested mechanism for the production of malondialdehyde during the autoxidation of polyunsaturated fatty acids. Nonenzymatic production of prostaglandin endoperoxides during autoxidation (Letter) J. Org. Chem. 40, 3615-3617,1975.
6. Esterbauer, H., Schaur,J.S., and Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med., 11, 81-128, 1991.
7. Frankel, E.N., and Neff, W.E., Formation of malondialdehyde from lipid oxidation products. Biochim. Biophys. Acta., 754, 264-270, 1983,
8. Fu, M.-X., Requena, J.R., Jenkins, T.J., Baynes, J.W., Thorpe, S.R., The advanced glycation end product, Nε- (carboxymethyl)lysine, is a productof both lipid peroxidation and glycoxidation reactions. J. Biol. Chem., 271, 9982-9986,1996.
9. Haberland, M.E., Fong, D., and Cheng, L., Malondialdehyde- altered protein occurs in atheroma of Watanabe Heritable Hyperlipidemic rabbits. Science, 241, 215-217, 1988.
10. Jain, S.K., The accumulation of malondialdehyde, a product of fatty acid peroxidation, can disturb amino phospholipid organization in the membrane bilayer of human eryhrocytes. J. Biol. Chem., 259, 3391-3394, 1984.
11. Palinski,W., Rosenfeld, M.E., Yla-Herttuala, S., Gurtner, G.C., Socher, S.S., Butler, S.W., Parthasarathy, S., Carew, T.E., and Steinberg, D., Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA, 86, 1372-1376, 1989.
12. Wirtzum, J.L., and Steinberg, D., Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest., 88, 1785-1792, 1991.
13. Berliner, J.A., Navab, M., Fogelman, A.M., Frank, J.S., Demer, L.L., Edwards, P.A., Watson, A.D., and Lusis, A.J., Atherosclerosis: basic meachanisms. Oxidation, inflammation, and genetics. Circulation, 91, 2488-2496,1995.
14. Holvoet, p., Collen, D., Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis, 137 Suppl. S33-S38,1998.
15. Napoli, C., Quehenberger, O., De Nigris, F., Abete, P., Glass, C.K., Palinski, W., Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 14, 1996-2007, 2000.
16. Brand, K., Eisele, T., Kreusel, U., Page, M., Haas, H., Gerling, A., Kaltshmidt, C., et.al., Dysregulation of monocytic nuclear factor - kappa B by oxidized low-density lipoprotein. Arterioscler. Thromb. Vas. Biol., 17, 1901-1907,1997.
17. Ohkawa, H., Ohishi, N.,and Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95,351-358,1979.
18. Knight, J. A., Pieper, R. K., and McClellan, L., Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation. Clin. Chem., 34, 2433-2438, 1988.
19. Arıcı, H., İstatistik, Meteksan Yayınları, Ankara,1991.
20. İzbırak, A., Serum selenium levels in ischaemic heart disease. Hacettepe J. Biol. Chem. 35, 2, In press.
21. Korantzopoulos, P., Galaris, D., Papaioannides, D., Siogas, K., The possible role of oxidative stress in heart failure and the potential role of antioxidant intervention. Med. Sci. Monit., 9(6), 140-145, 2003.
22. Amaki, T., Suzuki, T., Nakamura, F., Hayashi, D., Imal, Y., Morita, H., Fukino, K., et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart, 90, 1211-1213, 2004.
23. Holvoet, P., Kritchevsky, S.B., Tracy, R. P., et al. The metabolic syndrome, circulating oxidized LDL and risk of myocardial infarction in well-functioning elderly people in the health, aging and body composition cohort. Diabetes, 53, 1068-1073, 2004
24. Bird, R.P., and Draper, H.H., Comperative studies on different methods of malondialdehyde determination. Methods Enzymol. 105, 299-305, 1984.
25. Sim, A.S., Salonikas, C., Naidoo, D., and Wilcken, D.E., Improved method for plasma malondialdehyde measurement by high-performance liquid choromatography using methyl malondialdehyde as an internal standart. J. Choromatogr. B Analty. Tech. Biomed. Life Sci., 785, 337-344, 2003.
26. Boaz, M., Matas, Z., Biro, A., Katzir, Z., Green, M., and Fainaru, M. et al., Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Ins. 56, 1078-1083,1999.
27. Boaz, M., Matas, Z., Biro, A., Katzir, Z., Green, M., and Fainaru, M. et al., Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am. J. Kidney Dis., 34, 438-444,1999.
28. Del Rio, D., Steward, A.J., and Pellegrini, N., A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nut. Met. and Cardiovas. Disease, 15 (4), 316-328, 2005.
29. Nand, N., Budhiraja, N., Singh, G.P., Sharma. M., and Aggarwal, H.K., Lipid peroxidation and vitamin E in ischaemic heart disease. J. Assoc. Physicians India, 45 (11), 839- 842, 1997.
30. Salonen, J.T., Salonen, R., Penttila, I., Herranen, J., et al. Serum fatty acids, apolipoproteins, selenium and vitamin oxidants and the risk of death from coronary artery disease. Am. J. Cardiol., 56, 226-231, 1985.
31. Steinberg, D., and Wirtzum, J. L., Lipoproteins and atherogenesis. Jama, 264 (23), 3046-3052, 1990.
32. Kharb, S., and Singh, G.P., Effect of smoking on lipid profile, lipid peroxidation and antioxidant status in normal subjects and in patients during and after acute myocardial infarction. Clin. Chim. Act., 302 (1-2), 213-219, 2000.
33. Herbacynka-Cedro, K., Kosiewicz-Wasek, B., Cedro, K., Wasek, W., et al., Supplementation with vitamins C and E suppresses leucocyte oxygene free radical production in patients with myocardial infarction. Eur. Heart J., 16 (8), 1044-1049, 1995.
34. Kumar, D., Lou, H., and Singal, P. K., Oxidative stress and apoptosis in heart dysfunction. Herz, 27, 662-668, 2002.
35. Hecker, M., and Ullrich, V., On the mechanism of prostacyclin and thromboxane A2 biosythesis. J. Biol. Chem., 264, 141-150, 1989.
36. Marnett, L. J., Lipid peroxidation-DNA damage by malondialdehyde. Mutat. Res., 424, 83-95,1999.
37. Vander Veen, L. A., Hashim, M. F., Shyr, Y., and Marnett, L. J., Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogeneous carcinogen malondialdehyde. Proc. Nat. Acad. Sci. USA, 100, 14247-14252, 2003.
38. Niedernhofer, L.J., Daniels, J. S., Rouzer, C. A., Greene, R. E., and Marnett, L.J., Malondialdehyde a product of lipid peroxidation is mutagenic in human cells. J. Biol. Chem., 278, 31426-31433, 2003.